一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Biomedicines >>article
Biomedicines

Biomedicines

IF: 3.9
Download PDF

Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in BRCA1/2-Proficient Cancer Cells

Published:14 April 2025 DOI: 10.3390/biomedicines13040958 PMID: 40299557
Danyang Zhou,?Wei Liu,?Yanyan Zhang,?Chong Li

Abstract

Background/Objectives: PARP inhibitors (PARPi) are pivotal to treating homologous recombination repair-deficient (HRD) cancers, particularly BRCA1/2-mutated ovarian and breast cancers. However, most ovarian and breast cancers harbor wild-type (WT) BRCA1/2, limiting PARPi eligibility. This study aims to identify an approved drug that could induce a BRCAness phenotype, thereby sensitizing WT BRCA cancers to PARPi. Methods: Ovarian and breast cancer cell lines with WT BRCA1/2 were treated with ivosidenib. HR repair efficiency was assessed via RAD51 foci formation and reporter assays. Synthetic lethality with PARPi was evaluated using viability and colony formation assays. Mechanistic studies included RNA-binding protein pulldown, co-immunoprecipitation, and functional analyses of DNA repair pathways. YTHDC2's role in HR was investigated through siRNA knockdown and rescue experiments. Results: Ivosidenib significantly reduced HR repair efficiency and sensitized cells to PARPi, inducing synthetic lethality. Mechanistically, ivosidenib directly bound YTHDC2, an m6A reader critical for HR. This interaction disrupted YTHDC2's ability to promote DNA double-strand break repair via HR, evidenced by impaired recruitment of repair proteins (e.g., BRCA1, RAD51) and accumulation of DNA damage (γH2AX foci). YTHDC2 knockdown phenocopied ivosidenib effects, while overexpression rescued HR defects. Conclusions: Ivosidenib induces BRCAness in WT BRCA ovarian and breast cancers by targeting YTHDC2, thereby suppressing HR repair and enhancing PARPi sensitivity. This uncovers a novel, metabolism-independent mechanism of ivosidenib, repositioning it as a therapeutic agent for HRD tumors. These findings propose a strategy to expand PARPi eligibility to WT BRCA cancers, addressing a critical unmet need in oncology.

Similar articles

IF:0.8

Andrographolide Induces Apoptosis in Gastric Cancer Cells through Reactivation of p53 and Inhibition of Mdm-2

Doklady Biochemistry and Biophysics Hongbo Gao, Hongyang Li,etc Published: 25 October 2021
IF:5.4

Modulation of Estrogen Receptor Alpha (ERα) and Tumor Suppressor Gene BRCA1 in Breast Cancer Cells by Bazedoxifene Acetate (BZA)

ACS Applied Energy Materials Monica Szmyd, Aisha Zanib,etc Published: 7 February 2024
IF:6.9

5-aza-2′-deoxycytidine induces telomere dysfunction in breast cancer cells

Biomedicine & Pharmacotherapy Sarah Al-dulaimi , Sheila Matta ,etc Published: 26 July 2024
杂多县| 浑源县| 杭州市| 彭山县| 津南区| 云林县| 大竹县| 徐州市| 奎屯市| 泰兴市| 沁阳市| 龙州县| 万山特区| 灌阳县| 西乌珠穆沁旗| 佛坪县| 上栗县| 抚远县| 芜湖县| 扶余县| 宣城市| 增城市| 汉川市| 虞城县| 淅川县| 丰镇市| 阿克苏市| 敦煌市| 龙里县| 岳阳市| 时尚| 宜良县| 玉山县| 涿鹿县| 寿宁县| 丽江市| 泗水县| 金塔县| 顺义区| 兰考县| 壤塘县|